FDA Issued Warning Letter to Houston Empower Pharmacy
The regulatory agency challenged the production and prescription practices regarding compounded GLP-1 medications.
Updated on Sept. 22, 2026 in Diabetes
Live Poll
Do you trust the safety of compounded GLP-1 weight loss drugs compared to FDA-approved versions?
The FDA issued a warning letter to the Houston-based Empower Pharmacy regarding its production of GLP-1 drugs, including tirzepatide and semaglutide. Federal regulators questioned the validity of medical justifications used for these compounded formulations.
Why it matters
The agency claims that the volume of these drugs produced and the presence of pre-generated prescriber justifications suggest that differences between compounded and FDA-approved versions may be pretextual. This action marks the fifth warning letter sent to the pharmacy since 2017.
FDA inspectors noted concerns during a November 2025 visit to the facility. Empower Pharmacy has now received five official warning letters from the federal agency since 2017.
The players
Empower Pharmacy
A Houston-based pharmacy specializing in compounded medications and serving roughly 70,000 patients weekly.
Food and Drug Administration
The federal agency responsible for protecting public health by ensuring the safety and efficacy of human and veterinary drugs.
The details
Regulators alleged that the pharmacy adds B vitamins to its drugs in a manner that serves no clear medical purpose. The letter also highlights concerns that telehealth platforms allow providers to select reasons for needing compounded drugs rather than providing unique patient justifications.
Timeline
The pharmacy received its first FDA warning letter in 2017.
Nearly 3 million prescriptions were filled between January 2024 and October 2024.
FDA inspectors visited the facility in November 2025.
The FDA officially dated the warning letter on September 18, 2026.
The agency released the document to the public on September 22, 2026.
Health Landscape
This enforcement action highlights the growing tension between regulatory oversight and the rising demand for compounded GLP-1 medications. It reflects a broader effort by the FDA to monitor the quality and necessity of non-approved drug formulations in the national healthcare system.
Patients who rely on compounded GLP-1 medications should consult their healthcare provider regarding the safety and origin of their prescriptions. The warning letter may lead to changes in availability for certain compounded drug formulations.
The takeaway
Healthcare consumers are encouraged to verify that their medications are sourced from reputable and compliant facilities. Understanding the difference between FDA-approved drugs and compounded versions can help patients make safer medical decisions.
Further reading
Learn more about ongoing regulatory updates regarding Diabetes treatments and industry compliance.
Live Poll
Do you trust the safety of compounded GLP-1 weight loss drugs compared to FDA-approved versions?
